TB4-Frag Side Effects: Safety Signals and Warnings
TB4-Frag safety concerns are compound-specific. The main listed side effects are No significant adverse effects in animal studies, Theoretical risk of hypotension, and Potential interaction with blood pressure regulation. The main warning signals are Not approved for any clinical use, Extremely short half-life limits practical application without continuous infusion or ACE inhibitor co-therapy, and Identical active molecule to Ac-SDKP; sourcing and nomenclature may overlap.
Direct Answer
Evidence for TB4-Frag is too preliminary to support a research protocol with confidence. There is no peer-reviewed published evidence for this specific thymosin beta-4 fragment in any therapeutic context. Thymosin beta-4 itself (the parent molecule) has more published preclinical data. This compound should not be selected over TB4 or other healing peptides with any actual evidence base.
- Evidence grade
- Level D
- Research status
- Preclinical
- Category
- Healing & Recovery
- Best for
- No validated application - TB4 fragment mechanistic curiosity only
Reported Side Effects
- No significant adverse effects in animal studies
- Theoretical risk of hypotension
- Potential interaction with blood pressure regulation
- Very limited safety data
Warnings
- Not approved for any clinical use
- Extremely short half-life limits practical application without continuous infusion or ACE inhibitor co-therapy
- Identical active molecule to Ac-SDKP; sourcing and nomenclature may overlap
- All evidence is preclinical
Known or Plausible Interactions
- ACE inhibitors (prevent degradation; significantly increase circulating levels)
- Chemotherapy agents (may protect hematopoietic stem cells)
- TGF-beta pathway modulators (potential additive anti-fibrotic effects)
Regulatory Context
TB4-Frag/Ac-SDKP is a research compound not approved for clinical use. It is not a controlled substance. Available from research peptide suppliers. Functionally identical to Ac-SDKP.
Evidence Snapshot
| Evidence grade | Level D |
|---|---|
| Research status | Preclinical |
| Best supported outcomes | Anti-Fibrotic Activity (Level D), Cardiac Function Preservation (Level D), and Stem Cell Protection During Chemotherapy (Level D) |
| Primary citation count | 2 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "TB4-Frag Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/tb4-frag-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.